Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EFPIA Highlights Europe ‘Lessons’ As Japan Ponders Policies

This article was originally published in PharmAsia News

Executive Summary

EFPIA remains cautious over moves in Japan towards a formal health technology assessment system and possible changes to the reimbursement pricing system, calling again for the maintenance of an environment conducive to pharma innovation and pointing to lessons from its experience in Europe.

You may also be interested in...



Japan Firms Up Cost-Effectiveness Plans As Industry Concerns Linger

Japan firms up proposals for expanded cost-effectiveness assessment scheme for selected drugs and devices after a policy committee outlines plans that could see associated price adjustments for reviewed products.

EFPIA Urges Japan To Consider New Funding Models

Amid intensifying official scrutiny of rising drug costs, the European industry federation EFPIA would like Japan to focus more on the measuring the actual benefits and health outcomes of new therapies, helped by new approaches and technology.

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: Pfizer to boost migraine presence via M&A; Roche’s immunotherapy ambitions take a hit; Biogen’s CEO search gets more complicated; Stoffels lays out new strategy for Galapagos; and mixed results for Japanese majors.

Topics

Related Companies

UsernamePublicRestriction

Register

SC088494

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel